`(TASKOR.DE.R
`
`IENT
`
`This Amendment is entered into as of 22th July 201 1 by and between Novartis Pharma AO
`("Novartis;'), witll its rincioai lace of business at Lichtstrasse 35, CH 4056 Basel;
`?vit . ·ts principal. offices locl:l.ted at
`Switzerland . and
`and amends the terms of the
`eve op.meht Agreement between ■■■■■■■11ated 27th January 2009 (the
`"Development Agreement") which terms are hereby deemed amended for the purposes hereof
`and otherwise ratified.
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(US)00006151
`
`Novartis Exhibit 2155.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`Novartis Exhibit 2155.002
`Regeneron v. Novartis, IPR202 1-008 16
`
`Novartis Exhibit 2155.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Regeneron v. Novartis, IPR2021-00816
`
`Novartis Exhibit 2155.003
`
`Novartis Exhibit 2155.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`Novartis Exhibit 2155.004
`Regeneron v. Novartis, IPR202 1-008 16
`
`Novartis Exhibit 2155.004
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`Novartis Exhibit 2155.005
`Regeneron v. Novartis, IPR202 1-008 16
`
`Novartis Exhibit 2155.005
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`Novartis Exhibit 2155.006
`Regeneron v. Novartis, IPR202 1-008 16
`
`Novartis Exhibit 2155.006
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`Novartis Exhibit 2155.007
`Regeneron v. Novartis, IPR202 1-008 16
`
`Novartis Exhibit 2155.007
`Regeneron v. Novartis, IPR2021-00816
`
`